

AMENDMENTS TO THE CLAIMSIn the Claims:

1. (Currently Amended) A conjugate of formula

(metal complexing chelating agent)-((Y)_m-A-NHR)_k,

wherein the metal chelating agent has 4 to 8 metal donor atoms covalently linked together by a non-coordinating backbone in either an open chain or macrocyclic arrangement or combinations thereof, and the -(Y)_m-A-NHR substituent is attached at either the non-coordinating backbone or a metal donor atom of the chelating agent

where:

k is a natural number;

Y is the same or different at different locations within the molecule and is independently chosen from: an A group, a C₄₋₈ cycloheteroalkylene group, a C₄₋₈ cycloalkylene group, a C₅₋₁₂ arylene group, a C₃₋₁₂ heteroarylene group, or a polyalkyleneglycol, polyactic acid or polyglycolic acid moiety,

m is an integer of value 0-20,

A is a 3-10 atom chain of units selected from -CR₂-, -CR=CR-, -C≡C-, -NRCO-, -CONR-, -SO₂NR-, -NRSO₂-, or -CR₂ZCR₂- where Z is -CH₂-, O, S, Se or -NR-,

R is the same or different at different locations within the molecule and is independently chosen from H, C₁₋₄ alkyl, C₁₋₄ alkenyl, C₁₋₄ alkynyl, C₁₋₄ alkoxyalkyl or C₁₋₄ hydroxyalkyl,

with the proviso that the metal complexing chelating agent does not also have attached thereto a hypoxia localising moiety.

2. (Previously Presented) The conjugate of claim 1, wherein A is

$-\text{NHCO}(\text{CH}_2)_2\text{Z}(\text{CH}_2)_2-$, or

$-\text{SO}_2\text{NH}(\text{CH}_2)_2\text{Z}(\text{CH}_2)_2-$, or

$-(\text{CH}_2)_2\text{Z}(\text{CH}_2)_2-$.

3. (Previously Presented) The conjugate of claim 1, wherein Z is CH_2 .

4. (Previously Presented) The conjugate of claim 1, wherein the at least one substituent has the formula

$-(\text{Y})_m\text{A}-\text{NH}_2$.

5. (Previously Presented) The conjugate of claim 1, wherein the substituent has the formula

$-(\text{Y})_b\text{Ar}-\text{SO}_2\text{NH}(\text{CH}_2)_5\text{NH}_2$

where b is an integer of value 0 to 19 and Ar is an arylene or heteroarylene group.

6. (Cancelled) The conjugate of claim 1, wherein the metal complexing agent is a metal chelating agent.

6. (Currently Amended) The conjugate of claim 6 1, wherein the metal chelating agent is a diaminedioxime.

7. (Previously Presented) A metal complex of one or more radiometal or paramagnetic metal ions with the conjugate of claim 1.

8. (Original) ⁷ The metal complex of claim ~~8~~, wherein the radiometal is ^{99m}Tc, ¹¹¹In or ⁶⁷Ga.

9. ¹⁰ (Previously Presented) ⁷ The metal complex of claim ~~8~~ for use in the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.

10. ¹¹ (Previously Presented) ⁷ A kit for the preparation of the metal complex of claim ~~8~~.

11. ¹² (Previously Presented) ⁷ A vessel containing a unit dose for human administration of the metal complex of claim ~~8~~.

12. ¹³ (Previously Presented) ⁷ A method of preparing a composition for use in the diagnosis or therapy of thrombosis, atherosclerosis, inflammation or cancer, which method comprises bringing the metal complex of claim ~~8~~ into a form suitable for human administration.